Abstract 228P
Background
Cabozantinib, a novel TKI is an oral multitargeted inhibitor of VEGFR, MET and AXL kinases. The CABOSUN trial established the superiority of cabozantinib over sunitinib in newly diagnosed renal cell carcinoma (RCC) of intermediate or poor risk. Currently it is used as a single agent (intermediate risk) or in combination with nivolumab (intermediate and poor risk). However, data is lacking with respect to the real-world use patterns of cabozantinib.
Methods
In this study, we explored the use of single agent cabozantinib in advanced RCC in terms of dosing, effectiveness, tolerability, and toxicity profiles. This was a single center retrospective observational study from All India Institute of Medical Sciences, New Delhi, India. Data was collected retrospectively from prospectively maintained database. All eligible patients were aged 18 years or older, had measurable lesions, available case records, received at least 2 months of the drug and were evaluable for response.
Results
In total, 70 patients were identified with a median age of 53 years (interquartile, 47-65 years). Majority were males (81.4%). The different histologies were (clear cell 77.1%, papillary 11.4%, and translocation related 5.7%). 54.3% had prior nephrectomy. Majority had an IMDC score as intermediate (61.4%), followed by favorable (22.9%). Most common site of metastases was lung (60%) followed by bone (32.9%). Cabozantinib was started as the first line TKI in 60% (42/70), as 2nd line in 74.2% (23/31). Starting dose was 60mg in 27%, and 40mg in 73%. Dose reductions of cabozantinib were seen in 40.7% in 1st line, and 58.2% in 2nd line. Re escalation was done in 24.2%. Most common reason for dose reduction was diarrhea (64.7%). 35.7% had a partial response and 2.9% had a CR. ORR for overall population was 39.1%. Overall median PFS was 7.2 months. Most common adverse events were diarrhea in 42.7%, Hand-Foot skin reaction in 27.6%, mucositis in 17.8% and hepatotoxicity in 5.1%.
Conclusions
This study showed the practical dosing strategies and modifications of cabozantinib in the real world setting and how it differed from actual literature. We hope this study would help oncologists make better informed decisions while prescribing cabozantinib in advanced RCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India
Presenter: Amit Badola
Session: Poster Display
Resources:
Abstract
322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among the Asian population: A meta-analysis
Presenter: Wikania Wira Wiguna I Gede
Session: Poster Display
Resources:
Abstract
324P - All-<italic>trans</italic> retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity
Presenter: Bingjie Mei
Session: Poster Display
Resources:
Abstract
325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)
Presenter: Myong Cheol Lim
Session: Poster Display
Resources:
Abstract
327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer
Presenter: Swasthik Parampalli
Session: Poster Display
Resources:
Abstract
337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore
Presenter: Mohamed Haniffa Bin Hasan Mohamed
Session: Poster Display
Resources:
Abstract
338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis
Presenter: Yuce Wei
Session: Poster Display
Resources:
Abstract
339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
Presenter: Kenta Hayashino
Session: Poster Display
Resources:
Abstract
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract